| Elucidation of relationship between tumor size and survival in non‐small‐cell lung cancer patients can aid early decision making in clinical drug development Y Wang, C Sung, C Dartois, R Ramchandani, BP Booth, E Rock, ... Clinical Pharmacology & Therapeutics 86 (2), 167-174, 2009 | 239 | 2009 |
| Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004 K Brendel, C Dartois, E Comets, A Lemenuel-Diot, C Laveille, ... Clinical pharmacokinetics 46, 221-234, 2007 | 215 | 2007 |
| Phase I dose-escalation and-expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors J Rodon, I Braña, LL Siu, MJ De Jonge, N Homji, D Mills, E Di Tomaso, ... Investigational new drugs 32, 670-681, 2014 | 204 | 2014 |
| A review of mixed‐effects models of tumor growth and effects of anticancer drug treatment used in population analysis B Ribba, NH Holford, P Magni, I Trocóniz, I Gueorguieva, P Girard, C Sarr, ... CPT: pharmacometrics & systems pharmacology 3 (5), 1-10, 2014 | 194 | 2014 |
| Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey C Dartois, K Brendel, E Comets, CM Laffont, C Laveille, B Tranchand, ... British journal of clinical pharmacology 64 (5), 603-612, 2007 | 110 | 2007 |
| A Dynamic Model of Hand‐and‐Foot Syndrome in Patients Receiving Capecitabine E Hénin, B You, E VanCutsem, PM Hoff, J Cassidy, C Twelves, ... Clinical Pharmacology & Therapeutics 85 (4), 418-425, 2009 | 54 | 2009 |
| Evaluation of uncertainty parameters estimated by different population PK software and methods C Dartois, A Lemenuel-Diot, C Laveille, B Tranchand, M Tod, P Girard Journal of pharmacokinetics and pharmacodynamics 34, 289-311, 2007 | 46 | 2007 |
| Pharmacometrics Markup Language (PharmML): opening new perspectives for model exchange in drug development MJ Swat, S Moodie, SM Wimalaratne, NR Kristensen, M Lavielle, A Mari, ... CPT: pharmacometrics & systems pharmacology 4 (6), 316-319, 2015 | 41 | 2015 |
| Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial A Stein, W Wang, AA Carter, O Chiparus, N Hollaender, H Kim, RJ Motzer, ... BMC cancer 12 (1), 1-10, 2012 | 41 | 2012 |
| Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease C Dartois, G Freyer, M Michallet, E Hénin, B You, I Darlavoix, ... Clinical pharmacokinetics 46, 417-432, 2007 | 15 | 2007 |
| A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis, CPT: Pharmacometrics Syst B Ribba, NH Holford, P Magni, I Trocóniz, I Gueorguieva, P Girard, C Sarr, ... Pharmacol 3, 1-10, 2014 | 14 | 2014 |
| Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease U Schmid, B Weber, C Sarr, M Freiwald BMC Pulmonary Medicine 21 (1), 244, 2021 | 11 | 2021 |
| Clinical importance of including new and nontarget lesion assessment of disease progression (PD) to predict overall survival (OS): Implications for randomized phase II study … WL Mietlowski, W Bao, PA Wood, DE Williams, M El-Hashimy, C Sarr, ... ASCO Annual Meeting Proceedings 30 (15_suppl), 2543, 2012 | 4 | 2012 |
| Population pharmacokinetic analysis of peginterferon alfa-2a (40KD) supports use of BSA-category based dosing in children with chronic hepatitis B: PEG-B-ACTIVE pharmacokinetic … C Sarr, H Deng, E Snoeck, H Zhang, N Assy, Y Lobzin, A Potapov, ... Hepatology 63, 929A, 2016 | 3 | 2016 |
| A Phase I dose escalation and expansion trial of BKM120, An oral pan-PI3K Inhibitor, in patients with advanced solid tumors: Analysis of pharmacodynamic biomarker data J Rodon, J Bendell, ARA Razak, MJA De Jonge, F Eskens, E Di Tomaso, ... Annals of Oncology 23, ix158-ix159, 2012 | 3 | 2012 |
| Quantifying the effect of everolimus on both tumor growth and new metastases in metastatic renal cell carcinoma (RCC): A dynamic tumor model of the RECORD-1 phase III trial. AM Stein, A Carter, N Hollaender, RJ Motzer, C Sarr ASCO Annual Meeting Proceedings 29 (15_suppl), 4602, 2011 | 3 | 2011 |
| Clinical pharmacokinetic-pharmacodynamic (PK/PD) modeling study of the novel dual PI3K/mTOR inhibitor BEZ235. D Bottino, J Tabernero, HA Burris, C Britten, LC Chen, JC Bendell, ... ASCO Annual Meeting Proceedings 29 (15_suppl), 3056, 2011 | 2 | 2011 |
| Impact of handling missing PK data on PD estimation–explicit modeling of BLQ data in WinBUGS® reduced bias in the PD predictions–a preclinical example C Dartois, M Looby, H He, JL Steimer, G Pillai | 2 | 2007 |
| Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder SL Walsh, SD Comer, JA Zdovc, C Sarr, M Björnsson, K Strandgården, ... Neuropsychopharmacology, 1-8, 2024 | 1 | 2024 |
| Mathematical modeling of patient-level hemoglobin delineates ruxolitinib’s complex mechanism of action and quantifies anemia risk C Sarr, S Urva, J Nedelman, W Sallas, V Stalbovskaya, P Gopalakrishna, ... Blood 124 (21), 3228, 2014 | 1 | 2014 |
